Background. Gentamicin is often used to treat infective endocarditis (IE). Gentamicin is highly effective, but its applicability is reduced by its nephrotoxic effect. The aim of this study was to quantify the nephrotoxic effect of gentamicin and the association between the nephrotoxic effect and mortality in patients with IE.
gentamicin treatment is recommended for periods with a range between 3-5 days to treat native valve staphylococcal IE and as many as 6 weeks for patients with enterococcal IE [1] [2] [3] . Because of the toxic effects of AGs, especially the nephrotoxic effects, it has been debated whether AGs should be abandoned and replaced by other antibiotics [4] [5] [6] . In previous studies, it was suggested that kidney-function impairment in patients with IE is a prognostic factor with regard to both morbidity and mortality [7] [8] [9] . Such an impairment can have numerous causes, including complications with IE, surgery, and adverse effects of antibiotics [10] . However, these studies do not address the change in kidney function during IE treatment or the possible impact the change in kidney function may have on the prognosis. In addition, the relationship between changes in kidney function and duration of gentamicin treatment for IE has not been evaluated previously. The aim of the present study was to measure changes in renal function, as estimated by changes in endogenous creatinine clearance, in relation to duration of gentamicin treatment in patients with IE. Second, we evaluated the impact on postdischarge mortality of the overall change in estimated endogenous creatinine clearance (EECC), defined as the difference between EECC at the time of hospital admission and EECC at hospital discharge.
PATIENTS, MATERIALS, AND METHODS
Database. On 1 October 2002, a prospective collection of data was started from all consecutive patients who received a diagnosis of IE at 2 tertiary care heart centers in Copenhagen, Denmark. These 2 hospitals are the only tertiary care heart centers in a catchment area comprising 12.4 million people. The diagnosis of IE is based on clinical, microbiological, and echocardiographic findings. In addition, the diagnosis was evaluated using the revised Duke criteria suggested by Li et al. [11] . Data collection is based on a standard case report form that includes 1250 variables. Data include demographic characteristics; medical history; physical examination findings; results of blood tests, including culture of blood samples; electrocardiogram data; antibiotic and surgical treatments; and findings of both transthoracic and transesophageal echocardiography. Data were recorded at the time of diagnosis, at hospital admission, during hospitalization, and at hospital discharge. Patients were enrolled prospectively in the database if they met the revised criteria of having definite or possible IE. Patients with possible IE were included only if they received the same treatment as did patients with definite IE. The few patients who were examined at the centers but were treated at a different hospital were not included in the database. The database was approved by the Danish Data Supervisory Committee.
Study population. In the present study, all patients who received a diagnosis of IE from 1 October 2002 through 30 June 2007 were included. Data on 373 patients were collected and were later verified.
Kidney function. To measure kidney function, we approximated patient glomerular filtration rate by calculating the EECC at the time of diagnosis with equations that were based on Kampmann et al. [12] and Siersbaek-Nielsen et al. [13] Treatment. All patients received antibiotic and surgical treatment in accordance with the recent international guidelines on IE [2, 14] . The choice of antibiotics was based on results of culture of blood samples obtained for high-level disk susceptibility tests. MICs of the antibiotics and other in vitro tests were performed at the discretion of the microbiologists. No patients received gentamicin unless it was recommended by the microbiologists.
Gentamicin dosing was individualized for all patients and was guided by daily serum creatinine and trough serum gentamicin concentrations. Most patients received multiple daily doses of gentamicin. Blood for trough gentamicin determination was obtained in the morning immediately before administration of the morning dose. If the serum gentamicin level was 11 mg/mL, gentamicin was withheld; if the level was 0.5-1 mg/mL, the dose was reduced by 50%, and subsequent doses were then adjusted accordingly. The goal was a trough serum gentamicin level !0.5 mg/mL. Duration of gentamicin treatment was the total number of treatment days from the time of hospital admission.
Follow-up. All data were included in a database that includes information on hospital admissions and information on death through use of each patient's civil registration number. With regard to postdischarge mortality, the database was updated on 31 October 2007. Therefore, follow-up time for mortality was at least 4 months for every patient in the present study population. The follow-up time for mortality includes the days of hospitalization; therefore, the follow-up time has a range of 1-1820 days (median, 562 days), because some patients died within 24 h after diagnosis.
Statistics. All data are expressed as or median mean ‫ע‬ SD (range). The statistical evaluation of 2 groups was performed with a 2-sample Student's t test when the data were normally distributed. When the distribution was skewed, the MannWhitney U test was used. In evaluation of 12 groups, the Kruskal-Wallis test was used. Fisher's exact test was used to evaluate binomial data. A P value !.05 was considered to be statistically significant for 2-sided tests. Associations between EECC change and different covariates were analyzed using multivariate regression models, as follows: logistic regression for binary data, an EECC decrease of р10% or 110%, or linear regression, in which the EECC change was used as a continuous variable. In these analyses, we used the gentamicin treatment group-(1) no gentamicin, (2) treatment for р1 week, (3) treatment for 11 week and р2 weeks, (4) treatment for 12 weeks and р4 weeks, and (5) treatment for 14 weeks-as the variable. Associations between mortality and different covariates were analyzed by Cox's proportional hazards regression model. For the Cox analysis, EECC at admission was analyzed using a continuous scale of 10 mL/min. For all multivariate analyses, age was used as the underlying time scale, which ensures optimal adjustment for age. , where the option in brackets indicates the reference level. Relative risks were calculated as the proportional hazard ratio (HR). The proportional assumptions of the hazards were checked by log-log survivor plots for each variable, while controlling for sex and age. We tested for interactions between EECC at admission and age, sex, diabetes, prosthetic valves, embolic event, dialysis, dyspnoea, Duke positive, pacemaker, predisposition, and microbiological etiology for each group.
The associations between EECC change during admission and at end points were also analyzed by Cox's proportional hazards regression model. Again, age was used as the underlying time scale, to ensure optimal adjustment for age; sex ([male], female) was treated as a categorical dummy variable.
All analyses were performed using SAS, version 8.02 (SAS Institute), and SPSS, version 15.0.0 (SPSS).
RESULTS
The mean patient age was years; 261 (70.0%) of 62.0 ‫ע‬ 14.8 the 373 patients were men. All patients had either definite (336 patients [90.1%]) or possible (37 patients [9.9%]) IE. Two hundred twenty-seven patients (60.9%) were predisposed to IE, Enterococcus infection 7 (16) 4 (7) 4 (7) 12 (16) 19 (38) according to the Duke criteria. The characteristics of the study population at hospital admission are listed in table 1. Patients were divided into 2 groups: one in which gentamicin was never a part of the treatment (86 patients) and another in which gentamicin was part of treatment (287 patients). The mean number of days of gentamicin treatment in the latter group was 17 days (range, 1-69). The 2 groups differed in a few characteristics: in the "no-gentamicin" group, there was a lower EECC, and there was a larger percentage of patients who had diabetes, who had conduction block, and who were undergoing dialysis. In addition, more patients in the no-gentamicin group had a pacemaker or an implantable cardioverter defibrillator. Total mortality during the follow-up period, starting on the day of hospital admission, was significantly higher in the nogentamicin group, with a trend toward higher in-hospital mortality (table 2) . No differences were found in the other outcome data. In a univariate analysis, a higher mortality rate was associated with age (per year increase) (HR, 1.04; 95% CI, 1.02-1.05), dialysis (HR, 2.7; 95% CI, 1.7-4.3), EECC at diagnosis (per 10-mL/min decrease) (HR, 1.18; 1.12-1.24), and Staphylococcus aureus infection (HR, 1.7; 1.2-2.4). Surgery (HR, 0.51; 95% CI, 0.36-0.72) and Streptococcus infection (HR, 0.6; 0.4-0.9) were associated with a lower mortality rate. In a multivariate model, only age (HR, 1.03; 95% CI, 1.01-1.04) and EECC at diagnosis (per 10-mL/min decrease) (HR, 1.11; 95% CI, 1.03-1.19) remained significantly associated with mortality, a borderline lower mortality in patients who underwent surgery was found (HR, 0.68; 95% CI, 0.47-1.00;
). No other P p .05 associations were revealed.
Two hundred eighty-six patients had not been undergoing dialysis during their hospital stay and were discharged from the hospital. They were divided into 5 strata by duration of gentamicin treatment, as follows: (1) 1%) . The 5 groups differed significantly in distribution of these 3 microorganisms, as well as in coagulase-negative Staphylococcus species. Accordingly, S. aureus was the main bacterium in the no-gentamicin and in the р1 week groups. In the 11 week and р2 week groups and the 12 week and р4 week groups, the main bacterium was Streptococcus species, and in the 14 weeks group, Enterococcus species were most commonly found.
The impact of gentamicin on EECC from diagnosis to hospital discharge was reflected in a mean decrease of 8.6% in the gentamicin group and an increase of 2.3% in the group not receiving gentamicin ( ). Within the group of 317 pa-P p .008 tients discharged from the hospital, no significant difference was found in the decrease of EECC between patients who underwent surgery (decrease, 5.8 mL/min; 172 patients) and those who did not undergo surgery (decrease, 6.1 mL/min; 145 patients). However, we found a significant linear correlation between the EECC changes and the duration of gentamicin treatment; the decrease of EECC was 0.5% per day of gentamicin treatment ( ). Analysis was adjusted for age and sex P p .002 ( figure 1 ). In the multivariate linear regression model, only gentamicin groups were significantly associated with EECC change ( ). We also tested for a difference between gen-P ! .003 tamicin plus vancomycin versus b-lactam plus gentamicin with regard to change in EECC and mortality. No significant difference was found in either the univariate analysis or the multivariate analysis. When EECC change was treated as a binary variable (р10% or 110%), the only variable associated with EECC change other than gentamicin group was age (table 4) .
To include in-hospital mortality in the multivariate analysis, we constructed a binary composite end point, as follows: (1) EECC increase or decrease !10% and discharged from the hospital or (2) EECC decrease 110% or in-hospital fatality. The only significant association was age ( ). P p .001 To evaluate the effect of gentamicin and in-hospital changes in renal function on long-term survival, the 241 patients who were treated with gentamicin and who were discharged from the hospital were divided into quartiles according to their percentage change in EECC. After adjustment for age and sex, the cumulative survival for the 4 groups was practically indistinguishable ( ), as seen in the Kaplan-Meier plot (figure P p .916 2). To reduce the bias of infections with a broad spectrum of microorganisms, the analysis was repeated for patients with IE due to only Streptococcus or Enterococcus species (136 patients). The results, as seen in figure 3 , remained virtually unchanged and showed no relationship between mortality and changes in EECC during hospitalization ( ). P p .878
DISCUSSION
In this study, we have demonstrated a significant and proportional relationship between duration of gentamicin treatment and change in EECC in patients with IE. The greater the number of gentamicin treatment days, the greater the decrease in EECC, with a mean decrease of 0.5% in EECC for every day of gentamicin treatment. Importantly however, this renal-function decrease during hospital stay was not related to postdischarge mortality.
AGs are potent bactericidal antibiotics that target both the outer membrane and the ribosome of the bacterium. AGs are widely used to treat severe bacteremia and in patients with IE, but the role of AG for the treatment of septicemia has recently been challenged. In a systematic Cochrane database review of b-lactam antibiotic monotherapy versus b-lactam-AG antibiotic combination therapy for septicemia, Paul et al. [15] concluded that the addition of an AG to b-lactam in treatment of septicemia should be discouraged, because all-cause fatality rates were unchanged with the combination treatment, and the combination treatment carried a significant risk of nephrotoxicity. In a recently published, large historical cohort study, Freundlich et al. [6] compared the mortality and risk of increase in serum creatinine level in septic patients who received an AG with patients who did not receive an AG; one-half of their patients received an AG for !2 days, and 180% received an AG for !5 days. Freundlich et al. [6] found that AG, used for this short treatment period as part of a combination therapy, was not associated with either a decreased mortality rate or a significant increase in serum creatinine level of 145 mmol/L over Figure 2 . Kaplan-Meier plot of cumulative survival after hospital discharge for 241 patients with infective endocarditis, by percentage change in endogenous creatinine clearance (EECC) from diagnosis to hospital discharge. Patients are divided into quartiles, with EECC quartile intervals as follows: 1st, 17.3%; 2nd, between 7.3% and Ϫ11%; 3rd, between Ϫ11.3% and Ϫ21%; and 4th, less than Ϫ21%. Kaplan-Meier plot of cumulative survival after hospital discharge for 136 patients with infective endocarditis by percentage change in endogenous creatinine clearance (EECC) from diagnosis to hospital discharge. All patients had either Streptococcus or Enterococcus species as the causative microorganism. Patients are divided into quartiles, with EECC quartile intervals as follows: 1st, 17%; 2nd, between 7% and Ϫ10.3%; 3rd, between Ϫ10.3% and Ϫ28%; and 4th, less than Ϫ28%.
baseline. They did, however, find a trend toward an association between AG and an increase in serum creatinine level. Additionally, in a randomized study of daptomycin to treat S. aureus bacteremia and IE, Fowler et al. [16] reported a renal dysfunction occurrence of 26.6% in the standard therapy group, which received a mean of 4 days of gentamicin treatment, but only an 11.0% occurrence in the group treated with daptomycin.
Other studies have shown that impaired kidney function is prognostic for the mortality of not only patients with IE [7, 8] , but also of patients who experience heart failure [17] [18] [19] and patients with ischemic heart disease [20] who undergo coronary artery bypass surgery [21] . The prognostic factor of kidney function is important, because patients with IE are more liable to experience renal-function impairment because of a number of circumstances, including development of glomerulonephritis, acute interstitial nephritis, embolic events involving the kidneys, and septic shock. These events are typically present at the time of hospital admission or occur in the early phase of treatment of IE [22] . Surgical procedures involving frail patients and the microbiological agent itself are also significant additional factors. IE due to S. aureus has a particularly high association with the development of renal impairment, often because of septic emboli, and is seen in as many as 40%-50% of subjects [10, 23] .
Although AG is known to be nephrotoxic, the detrimental effect of gentamicin on renal function has not been evaluated elsewhere in patients with IE. This is quite surprising, because 180% of patients with IE are treated with gentamicin, often for much longer periods than for patients with other kinds of bacteremia.
Our present data show that the duration of gentamicin treatment and the degree of nephrotoxicity are related, even with strict monitoring of gentamicin concentrations in plasma. We found that the only group that showed a mean increase in EECC was the no-gentamicin group, despite the fact that this group had the lowest baseline EECC and a high percentage of S. aureus infections. The lower baseline EECC and high percentage of S. aureus infections might, in part, explain the higher mortality rate of this group. In addition, age was the only variable associated with EECC change other than the receipt of gentamicin. These findings strongly suggest that the progressive decrease in renal function is attributable primarily to prolonged gentamicin treatment.
Another question is whether this nephrotoxicity has a negative effect on outcome. To study this issue, we divided into quartiles all patients who were not undergoing dialysis, who were discharged from the hospital, and who were treated with gentamicin, according to the change in EECC during the hospital stay. We found absolutely no correlation between the change in EECC and postdischarge mortality; thus, our data do not support this theory. One explanation could be that the gentamicin-induced renal-function decrease is reversible.
Because IE attributable to S. aureus is usually treated with an AG for only a few days, if at all, the study population was further reduced to include IE attributable solely to Streptococcus species and Enterococcus species, because these 2 microbiological agents are among the least likely to cause renal impairment [10] and because patients with these infections typically receive gentamicin for longer periods of time. Still, we could show no relationship between mortality and the nephrotoxic effect of gentamicin.
In the univariate analysis, we found that, in addition to baseline EECC, increased mortality was associated with age, diabetes, and S. aureus infection, whereas surgery and Streptococcus species were associated with a significantly better survival rate. These findings are in accordance with most previous studies [8, [24] [25] [26] [27] [28] . However, in the multivariate analysis, only age and baseline EECC remained significant factors, with a borderline lower mortality rate in patients who underwent surgical procedures.
The primary study limitations are that there was a selection bias, because all patients were treated at tertiary heart centers, and that the study was not randomized; although we performed a multivariate analysis, microbiological etiology is likely to be of some consequence.
In summary, this study finds a progressive nephrotoxic effect of gentamicin in relation to treatment duration. Even though baseline renal function is an independent prognostic marker of mortality, we found no association between mortality and a gentamicin-induced decrease in renal function during hospitalization to treat IE. Our study does not support the abolishment of AG in treatment of IE.
